A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Octreotide (BYNFEZIA Pen)

Somatostatin Analog class · 9 generic manufacturers · 38 ANDAs filed at FDA.

First FDA approval1988-10-21
Generic availableYes · 9 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$24.4M in CY2024 Part D spend25K claims · 6K beneficiaries · 329 plans surveyed

Lowest NADAC
$2.64/unit
16 NDCs benchmarked, lowest of all strengths.
Average NADAC
$906.67
Across all dosage forms in distribution.
Highest NADAC
$6680.85
Wide spread — brand-strength NDCs still in market.
Plans with PA
1238 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Octreotide used for?

Octreotide is a Somatostatin Analog medication tracked in Medicare Part D.

Is there a generic for Octreotide?

Yes. 38 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Octreotide?

Across 329 Part D plans, Octreotide averages $906.67/unit (NADAC). Lowest available: $2.64/unit. Highest in distribution: $6680.85/unit.

Is Octreotide on the FDA shortage list?

No. Octreotide is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Somatostatin Analog1 alternative in D1
01
Pasireotide
Brand: Signifor
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (16 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.